SecBot SecBot
8-K ·Filed Jun 10, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001104659-26-072326
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No actionable trading signal. This is a standard post-annual meeting filing with routine director elections and equity plan amendments. Monitor for operational or pipeline updates from upcoming earnings or press releases.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.31
T+0 close · Jun 10, 2026 · via day close
Latest settled
+13.00%
T+60 · $7.13
Vs SPY
+8.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $6.31entry
  2. T+1 · 5mo ago +2.38%α +1.84% · $6.46
  3. T+5 · 5mo ago +7.92%α +7.49% · $6.81
  4. T+20 · 4mo ago +17.27%α +15.38% · $7.40
  5. T+60 · 2mo ago +13.00%α +8.60% · $7.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approved amendments to the company's 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to include pre-funded warrants in the evergreen share calculation. Two Class II directors were elected and Ernst & Young was ratified as auditor. This is a routine governance filing with no material financial impact.

Key Facts

  • Stockholders approved Amendment No. 1 to the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan, adding pre-funded warrants to the evergreen formula's outstanding share count.
  • Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were elected as Class II directors.
  • Ernst & Young LLP was ratified as independent auditor for fiscal year 2026.
  • 38,820,616 shares outstanding as of record date April 13, 2026; 33,190,234 shares present at meeting.
  • The 2021 Plan Amendment passed with 14,686,713 for, 9,566,186 against; the ESPP Amendment passed with 16,780,217 for, 7,475,514 against.

Financial Impact

No financial impact. The equity plan amendments are administrative and do not change share reserve amounts or dilutive limits directly.

Risk Factors

  • No material risks identified in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-072326
Document: tm2617532d1_ex10-1.htm0001104659-26-072326
Document: tm2617532d1_ex10-2.htm0001104659-26-072326
Document: 0001104659-26-072326-index-headers.html0001104659-26-072326
Document: 0001104659-26-072326-index.html0001104659-26-072326
Document: 0001104659-26-072326.txt0001104659-26-072326

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026